Neurocrine Biosciences Inc. (NBIX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Neurocrine Biosciences In... (NBIX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

139.49

-3.54 (-2.48%)

At close: Jan 14, 2025, 3:59 PM

139.51

0.01%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	136.01
Market Cap	14.12B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	3.75
PE Ratio (ttm)	37.2
Forward PE	n/a
Analyst	Buy

Ask	152.29
Volume	746,933
Avg. Volume (20D)	987,604
Open	142.46
Previous Close	143.03
Day's Range	139.42 - 144.22
52-Week Range	110.95 - 157.98
Beta	undefined

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ON...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 23, 1996

Employees 1,700

Stock Exchange NASDAQ

Ticker Symbol NBIX

Website https://www.neurocrine.com

Analyst Forecast

According to 22 analyst ratings, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $164, which is an increase of 17.57% from the latest price.

Buy 77.27%

Hold 22.73%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Neurocrine Biosciences Inc. is scheduled to release its earnings on Feb 5, 2025, before market opens.
Analysts project revenue of $629.72M, reflecting a 22.23% YoY growth and earnings per share of 1.92, making a 24.68% increase YoY.

Why Price Moved

1 month ago · Source

+5.01%

Neurocrine Biosciences shares are trading higher. ... Unlock content with Pro Subscription

2 months ago · Source

+7.01%

Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised annual valbenazine revenue outlook. It also authorized $300 million stock buyback.

News

3 weeks ago · https://thefly.com

Neurocrine price target raised to $182 from $172 at BofA

BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices...

4 weeks ago · seekingalpha.com

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transf...

1 month ago · investors.com

Neurocrine Wins FDA Approval For Genetic Disorder Drug

Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder D...

1 month ago · reuters.com

US FDA approves Neurocrine Biosciences' genetic disorder drug

The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.

2 months ago · seekingalpha.com

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slo...

2 months ago · seekingalpha.com

Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Office...

2 months ago · zacks.com

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall ...

2 months ago · zacks.com

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $0.82 per share a year ago.

2 months ago · zacks.com

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.